Evidence map›Paper›PMID 39812937›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC).

Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek, Hilal Karakas, Selver Isık, Murat Günaltılı, Aysun Fatma Akkus, Deniz Tural and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hatice BolekDepartment of Medical Oncology, Ankara University School of Medicine, 06590, Ankara, Türkiye.
Omer Faruk KuzuDepartment of Medical Oncology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Türkiye.
Elif Sertesen CamozDepartment of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Türkiye.
Saadet SimDepartment of Medical Oncology, Ege University School of Medicine, Izmir, Türkiye.
Serhat SekmekDepartment of Medical Oncology, Bilkent City Hospital, Ankara, Türkiye.
Hilal KarakasDepartment of Medical Oncology, Bilkent City Hospital, Ankara, Türkiye.
Selver IsıkDepartment of Medical Oncology, Marmara University School of Medicine, Istanbul, Türkiye.
Murat GünaltılıDepartment of Medical Oncology, Cerrahpasa School of Medicine, Istanbul, Türkiye.
Aysun Fatma AkkusDepartment of Medical Oncology, Trakya University School of Medicine, Edirne, Türkiye.
Deniz TuralDepartment of Medical Oncology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye.
Cagatay ArslanMedical Point Hospital, Izmir University of Economics, Izmir, Türkiye.
Sema Sezin GoksuDepartment of Medical Oncology, Akdeniz University School of Medicine, Antalya, Türkiye.
Ozlem Nuray SeverDepartment of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Türkiye.
Nuri KaradurmusDepartment of Medical Oncology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Türkiye.
Cengiz KaracinDepartment of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Türkiye.
Mehmet Ali Nahit SendurDepartment of Medical Oncology, Bilkent City Hospital, Ankara, Türkiye.
Emre YekedüzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yuksel UrunDepartment of Medical Oncology, Ankara University School of Medicine, 06590, Ankara, Türkiye. yuksel.urun@ankara.edu.tr.ORCID http://orcid.org/0000-0002-9152-9887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIdentifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine kinase inhibitors (TKIs) as first-line therapy.

methodsA retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium Database. GLR was calculated by dividing the fasting glucose (mmol/L) by the lymphocyte count (×10

resultsThe analysis included a total of 598 patients. We found that progression-free survival (PFS) was significantly longer in the GLR-low group, with a median PFS of 15.05 months (95% CI 12.7-17.4) compared to 7.79 months (95% CI 6.6-9.0) in the GLR-high group (p < 0.001). Multivariate analysis identified GLR as an independent risk factor for poor PFS (HR 1.39, 95% CI 1.12-1.72; p = 0.003). Overall survival (OS) was also significantly longer in the GLR-low group, with a median OS of 38.47 months (95% CI, 30.9-46.0) compared to 24.15 months (95% CI 18.0-30.2) in the GLR-high group (p = 0.001). GLR was an independent predictor for OS in multivariate analysis (HR 1.45, 95% CI 1.12-1.86; p = 0.004).

conclusionThe GLR can be a valuable prognostic marker for glucose metabolism and systemic inflammatory status in this patient population. Our research highlights the potential prognostic value of GLR in patients with mRCC receiving TKIs, indicating its potential as a useful tool for clinical decision-making.

Indexed as

Blood GlucoseCarcinoma, Renal CellKidney NeoplasmsLymphocytesProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansLymphocyte CountMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesBlood GlucoseProtein Kinase InhibitorsTyrosine Kinase InhibitorsGLRGlucose-to-lymphocyte ratioRenal cell carcinomaTyrosine kinase inhibitor

Identifiers

PMID39812937
PMCPMC12178969

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.